Your browser doesn't support javascript.
loading
Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients.
Zhao, Wenjuan; Liu, Yi; Zhang, Mengdi; Cui, Zixin; Qu, Zhan; Li, Yiyang; Wan, Meijuan; Wang, Wen; Chen, Yunru; Shi, Lei; Li, Jianzhou; Ye, Feng.
Afiliación
  • Zhao W; Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
  • Liu Y; Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
  • Zhang M; Department of Nutrition, Xian Jiaotong University, Xi'an, China.
  • Cui Z; Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
  • Qu Z; Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
  • Li Y; Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
  • Wan M; Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
  • Wang W; Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
  • Chen Y; Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
  • Shi L; Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
  • Li J; Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
  • Ye F; Department of Infectious Diseases, The First Affiliated Hospital of Xian Jiaotong University, Xi'an, China.
Front Med (Lausanne) ; 11: 1399665, 2024.
Article en En | MEDLINE | ID: mdl-38895186
ABSTRACT

Background:

This study was aimed at investigating the dynamics of lipids and the effect of TAF on the lipid profile of patients including fatty liver disease in CHB patients.

Methods:

The data of TC, LDL-c, HDL-c, TG, and TC/HDL ratio were collected at baseline, 24 weeks, 48 weeks, 72 weeks, and 96 weeks. CHB patients with fatty liver at baseline were further analyzed in a subgroup.

Results:

A total of 137 CHB patients treated with TAF were enrolled in this study. During 96 weeks of TAF treatment, there was no significant change in TC, LDL-c, HDL-c, and TG level (P > 0.05). The TC/HDL-c ratio was increased with no significant change (+0.24, P > 0.05). In CHB patients with fatty liver (n = 48), TC, LDL-c, and TC/HDL-c ratio increased gradually during TAF treatment, TG levels increased to 146.63 mg/dL at 48 weeks (P = 0.057) and then decreased, but there was still no significant change compared with the baseline level by 96 weeks (P > 0.05).

Conclusion:

TAF treatment had a low effect on the lipid profile of CHB patients over the course of 96 weeks, and it was safe even in patients with fatty liver. Clinical trial registration [https//www.chictr.org.cn/showproj.html?proj=65123], identifier [ChiCTR2000041005].
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Med (Lausanne) Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Med (Lausanne) Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza